ID   NCOR2_HUMAN             Reviewed;        2525 AA.
AC   Q9Y618; O00613; O15416; O15421; Q13354; Q56D06; Q59GM0; Q9Y5U0;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   24-MAR-2009, sequence version 2.
DT   10-MAY-2017, entry version 191.
DE   RecName: Full=Nuclear receptor corepressor 2;
DE            Short=N-CoR2;
DE   AltName: Full=CTG repeat protein 26;
DE   AltName: Full=SMAP270;
DE   AltName: Full=Silencing mediator of retinoic acid and thyroid hormone receptor;
DE            Short=SMRT;
DE   AltName: Full=T3 receptor-associating factor;
DE            Short=TRAC;
DE   AltName: Full=Thyroid-, retinoic-acid-receptor-associated corepressor;
GN   Name=NCOR2; Synonyms=CTG26;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Fetal liver;
RX   PubMed=8813722; DOI=10.1210/mend.10.7.8813722;
RA   Sande S., Privalsky M.L.;
RT   "Identification of TRACs (T3 receptor-associating cofactors), a family
RT   of cofactors that associate with, and modulate the activity of,
RT   nuclear hormone receptors.";
RL   Mol. Endocrinol. 10:813-825(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND VARIANT THR-1707.
RC   TISSUE=Pituitary;
RX   PubMed=10077563; DOI=10.1073/pnas.96.6.2639;
RA   Ordentlich P., Downes M., Xie W., Genin A., Spinner N.B., Evans R.M.;
RT   "Unique forms of human and mouse nuclear receptor corepressor SMRT.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:2639-2644(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), AND VARIANT THR-1707.
RC   TISSUE=Cervix adenocarcinoma;
RX   PubMed=10097068; DOI=10.1073/pnas.96.7.3519;
RA   Park E.J., Schroen D.J., Yang M., Li H., Li L., Chen J.D.;
RT   "SMRTe, a silencing mediator for retinoid and thyroid hormone
RT   receptors-extended isoform that is more related to the nuclear
RT   receptor corepressor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:3519-3524(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), AND VARIANT THR-1707.
RA   Chen J.D.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-1451, AND VARIANT GLU-781.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 428-613.
RC   TISSUE=Brain cortex;
RX   PubMed=9225980; DOI=10.1007/s004390050476;
RA   Margolis R.L., Abraham M.R., Gatchell S.B., Li S.-H., Kidwai A.S.,
RA   Breschel T.S., Stine O.C., Callahan C., McInnis M.G., Ross C.A.;
RT   "cDNAs with long CAG trinucleotide repeats from human brain.";
RL   Hum. Genet. 100:114-122(1997).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1023-2525, AND VARIANT THR-1707.
RC   TISSUE=Cervix adenocarcinoma;
RX   PubMed=7566127; DOI=10.1038/377454a0;
RA   Chen J.D., Evans R.M.;
RT   "A transcriptional co-repressor that interacts with nuclear hormone
RT   receptors.";
RL   Nature 377:454-457(1995).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND COMPONENT OF THE N-COR
RP   COMPLEX WITH TBL1X AND HDAC3.
RX   PubMed=10809664;
RA   Guenther M.G., Lane W.S., Fischle W., Verdin E., Lazar M.A.,
RA   Shiekhattar R.;
RT   "A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-
RT   repeat protein linked to deafness.";
RL   Genes Dev. 14:1048-1057(2000).
RN   [10]
RP   COMPONENT OF THE N-COR COMPLEX WITH TBL1X AND HDAC3.
RX   PubMed=10944117; DOI=10.1093/emboj/19.16.4342;
RA   Li J., Wang J., Wang J., Nawaz Z., Liu J.M., Qin J., Wong J.;
RT   "Both corepressor proteins SMRT and N-CoR exist in large protein
RT   complexes containing HDAC3.";
RL   EMBO J. 19:4342-4350(2000).
RN   [11]
RP   INTERACTION WITH MINT.
RX   PubMed=11331609; DOI=10.1101/gad.871201;
RA   Shi Y., Downes M., Xie W., Kao H.-Y., Ordentlich P., Tsai C.-C.,
RA   Hon M., Evans R.M.;
RT   "Sharp, an inducible cofactor that integrates nuclear receptor
RT   repression and activation.";
RL   Genes Dev. 15:1140-1151(2001).
RN   [12]
RP   INTERACTION WITH CBFA2T3.
RX   PubMed=11533236; DOI=10.1128/MCB.21.19.6470-6483.2001;
RA   Amann J.M., Nip J., Strom D.K., Lutterbach B., Harada H., Lenny N.,
RA   Downing J.R., Meyers S., Hiebert S.W.;
RT   "ETO, a target of t(8;21) in acute leukemia, makes distinct contacts
RT   with multiple histone deacetylases and binds mSin3A through its
RT   oligomerization domain.";
RL   Mol. Cell. Biol. 21:6470-6483(2001).
RN   [13]
RP   COMPONENT OF THE N-COR COMPLEX WITH NCOR1; GPS2; TBL1X; TBL1R AND
RP   HDAC3.
RX   PubMed=11931768; DOI=10.1016/S1097-2765(02)00468-9;
RA   Zhang J., Kalkum M., Chait B.T., Roeder R.G.;
RT   "The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK
RT   pathway through the integral subunit GPS2.";
RL   Mol. Cell 9:611-623(2002).
RN   [14]
RP   INTERACTION WITH HDAC10.
RX   PubMed=11739383; DOI=10.1074/jbc.M108055200;
RA   Fischer D.D., Cai R., Bhatia U., Asselbergs F.A.M., Song C., Terry R.,
RA   Trogani N., Widmer R., Atadja P., Cohen D.;
RT   "Isolation and characterization of a novel class II histone
RT   deacetylase, HDAC10.";
RL   J. Biol. Chem. 277:6656-6666(2002).
RN   [15]
RP   INTERACTION WITH RARB.
RX   PubMed=12554770; DOI=10.1210/me.2002-0340;
RA   Hauksdottir H., Farboud B., Privalsky M.L.;
RT   "Retinoic acid receptors beta and gamma do not repress, but instead
RT   activate target gene transcription in both the absence and presence of
RT   hormone ligand.";
RL   Mol. Endocrinol. 17:373-385(2003).
RN   [16]
RP   INTERACTION WITH BCL6.
RX   PubMed=15454082; DOI=10.1016/j.cell.2004.09.014;
RA   Fujita N., Jaye D.L., Geigerman C., Akyildiz A., Mooney M.R.,
RA   Boss J.M., Wade P.A.;
RT   "MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte
RT   differentiation.";
RL   Cell 119:75-86(2004).
RN   [17]
RP   INTERACTION WITH ATXN1L.
RX   PubMed=16121196; DOI=10.1038/sj.emboj.7600785;
RA   Mizutani A., Wang L., Rajan H., Vig P.J.S., Alaynick W.A.,
RA   Thaler J.P., Tsai C.-C.;
RT   "Boat, an AXH domain protein, suppresses the cytotoxicity of mutant
RT   ataxin-1.";
RL   EMBO J. 24:3339-3351(2005).
RN   [18]
RP   ALTERNATIVE SPLICING (ISOFORM 5).
RX   PubMed=15632172; DOI=10.1074/jbc.M411514200;
RA   Goodson M.L., Jonas B.A., Privalsky M.L.;
RT   "Alternative mRNA splicing of SMRT creates functional diversity by
RT   generating corepressor isoforms with different affinities for
RT   different nuclear receptors.";
RL   J. Biol. Chem. 280:7493-7503(2005).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-149; SER-215; THR-1391;
RP   SER-2016 AND SER-2269, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-54, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [21]
RP   FUNCTION AS BCL6 COREPRESSOR, AND INTERACTION WITH BCL6.
RX   PubMed=18212045; DOI=10.1128/MCB.01400-07;
RA   Mendez L.M., Polo J.M., Yu J.J., Krupski M., Ding B.B., Melnick A.,
RA   Ye B.H.;
RT   "CtBP is an essential corepressor for BCL6 autoregulation.";
RL   Mol. Cell. Biol. 28:2175-2186(2008).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-149; SER-152; THR-156;
RP   SER-750; SER-753; SER-1259; THR-1391; SER-1487; SER-2065; THR-2073;
RP   SER-2234 AND SER-2269, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [24]
RP   INTERACTION WITH RXRA.
RX   PubMed=19786558; DOI=10.1124/mol.109.057000;
RA   Cho Y., Noshiro M., Choi M., Morita K., Kawamoto T., Fujimoto K.,
RA   Kato Y., Makishima M.;
RT   "The basic helix-loop-helix proteins differentiated embryo chondrocyte
RT   (DEC) 1 and DEC2 function as corepressors of retinoid X receptors.";
RL   Mol. Pharmacol. 76:1360-1369(2009).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-67; SER-149; SER-152;
RP   THR-553; SER-554; SER-939; SER-1331; SER-2057; SER-2065; SER-2068;
RP   SER-2069; SER-2234 AND SER-2269, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [26]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-878; LYS-959; LYS-1218;
RP   LYS-1248; LYS-1970 AND LYS-2037, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [27]
RP   INTERACTION WITH RARA, AND MUTAGENESIS OF ARG-2139; VAL-2141 AND
RP   THR-2142.
RX   PubMed=20543827; DOI=10.1038/nsmb.1855;
RA   le Maire A., Teyssier C., Erb C., Grimaldi M., Alvarez S.,
RA   de Lera A.R., Balaguer P., Gronemeyer H., Royer C.A., Germain P.,
RA   Bourguet W.;
RT   "A unique secondary-structure switch controls constitutive gene
RT   repression by retinoic acid receptor.";
RL   Nat. Struct. Mol. Biol. 17:801-807(2010).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-149; SER-152; SER-554;
RP   SER-956; SER-1872; SER-2214; SER-2234 AND SER-2269, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-149; SER-152; SER-956;
RP   SER-1786 AND SER-2269, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [31]
RP   FUNCTION AS BCL6 COREPRESSOR, INTERACTION WITH BCL6 AND HDAC3, AND
RP   IDENTIFICATION IN A COMPLEX WITH BCL6 AND BCOR.
RX   PubMed=23911289; DOI=10.1016/j.celrep.2013.06.016;
RA   Hatzi K., Jiang Y., Huang C., Garrett-Bakelman F., Gearhart M.D.,
RA   Giannopoulou E.G., Zumbo P., Kirouac K., Bhaskara S., Polo J.M.,
RA   Kormaksson M., Mackerell A.D. Jr., Xue F., Mason C.E., Hiebert S.W.,
RA   Prive G.G., Cerchietti L., Bardwell V.J., Elemento O., Melnick A.;
RT   "A hybrid mechanism of action for BCL6 in B cells defined by formation
RT   of functionally distinct complexes at enhancers and promoters.";
RL   Cell Rep. 4:578-588(2013).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-54; SER-67; SER-215;
RP   SER-493; SER-939; THR-946; SER-956; SER-1181; SER-1259; SER-1331;
RP   THR-1391; SER-1487; SER-1547; SER-1627; SER-1783; SER-1786; SER-2065;
RP   SER-2088; SER-2234; SER-2269 AND SER-2424, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [33]
RP   INTERACTION WITH DEAF1.
RX   PubMed=23372760; DOI=10.1371/journal.pone.0054715;
RA   Kateb F., Perrin H., Tripsianes K., Zou P., Spadaccini R.,
RA   Bottomley M., Franzmann T.M., Buchner J., Ansieau S., Sattler M.;
RT   "Structural and functional analysis of the DEAF-1 and BS69 MYND
RT   domains.";
RL   PLoS ONE 8:E54715-E54715(2013).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-149; SER-152; SER-215;
RP   SER-956; SER-2016; SER-2065 AND THR-2073, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [35]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-1661, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.O113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1422-1438 IN COMPLEX WITH
RP   BL6.
RX   PubMed=14690607; DOI=10.1016/S1097-2765(03)00454-4;
RA   Ahmad K.F., Melnick A., Lax S., Bouchard D., Liu J., Kiang C.L.,
RA   Mayer S., Takahashi S., Licht J.D., Prive G.G.;
RT   "Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain.";
RL   Mol. Cell 12:1551-1564(2003).
CC   -!- FUNCTION: Transcriptional corepressor. Mediates the
CC       transcriptional repression activity of some nuclear receptors by
CC       promoting chromatin condensation, thus preventing access of the
CC       basal transcription. Isoform 1 and isoform 5 have different
CC       affinities for different nuclear receptors. Involved in the
CC       regulation BCL6-dependent of the germinal center (GC) reactions,
CC       mainly through the control of the GC B-cells proliferation and
CC       survival. {ECO:0000269|PubMed:18212045,
CC       ECO:0000269|PubMed:23911289}.
CC   -!- SUBUNIT: Forms a large corepressor complex that contains SIN3A/B
CC       and histone deacetylases HDAC1 and HDAC2. This complex associates
CC       with the thyroid (TR) and the retinoid acid receptors (RAR) in the
CC       absence of ligand, and may stabilize their interaction with TFIIB.
CC       Interacts directly with RARA in the absence of ligand; the
CC       interaction represses RARA activity. Interacts (isoform SMRT) with
CC       HDAC10. Interacts with MINT. Component of the N-Cor repressor
CC       complex, at least composed of NCOR1, NCOR2, HDAC3, TBL1X, TBL1R,
CC       CORO2A and GPS2. Interacts with CBFA2T3 and ATXN1L. Interacts with
CC       RARB; the interaction is weak and does not repress RARB
CC       transactivational activity. Interacts with HDAC7 and C1D.
CC       Interacts with NR4A2; this interaction increases in the absence of
CC       PITX3. Interacts with BCL6 (via the BTB domain), required for BCL6
CC       transcriptional repressor activity on a subset of target genes.
CC       Forms ternary complexes with BCOR and BCL6 on target gene
CC       promoters but, on enhancer elements, interacts with BCL6 and HDAC3
CC       to repress proximal gene expression. May interact with DEAF1.
CC       Interacts with RXRA. Interacts with MECP2 (By similarity).
CC       {ECO:0000250|UniProtKB:Q9WU42, ECO:0000269|PubMed:11331609,
CC       ECO:0000269|PubMed:11533236, ECO:0000269|PubMed:11739383,
CC       ECO:0000269|PubMed:12554770, ECO:0000269|PubMed:14690607,
CC       ECO:0000269|PubMed:15454082, ECO:0000269|PubMed:16121196,
CC       ECO:0000269|PubMed:18212045, ECO:0000269|PubMed:19786558,
CC       ECO:0000269|PubMed:20543827, ECO:0000269|PubMed:23372760,
CC       ECO:0000269|PubMed:23911289}.
CC   -!- INTERACTION:
CC       P35869:AHR; NbExp=2; IntAct=EBI-80830, EBI-80780;
CC       P27540:ARNT; NbExp=2; IntAct=EBI-80830, EBI-80809;
CC       Q01094:E2F1; NbExp=2; IntAct=EBI-80830, EBI-448924;
CC       Q13547:HDAC1; NbExp=2; IntAct=EBI-80830, EBI-301834;
CC       Q15156:PML-RAR; NbExp=2; IntAct=EBI-80830, EBI-867256;
CC       Q06330:RBPJ; NbExp=3; IntAct=EBI-80830, EBI-632552;
CC       Q13573:SNW1; NbExp=4; IntAct=EBI-80830, EBI-632715;
CC       P04637:TP53; NbExp=7; IntAct=EBI-80830, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=SMRT-alpha, TRAC-2;
CC         IsoId=Q9Y618-1; Sequence=Displayed;
CC       Name=2; Synonyms=TRAC-1;
CC         IsoId=Q9Y618-2; Sequence=VSP_003412, VSP_003413;
CC         Note=Contains only the C-terminal receptor-interacting domain
CC         and acts as an antirepressor.;
CC       Name=3; Synonyms=h-SMRT;
CC         IsoId=Q9Y618-3; Sequence=VSP_036596;
CC       Name=4; Synonyms=SMRTe;
CC         IsoId=Q9Y618-4; Sequence=VSP_036595;
CC       Name=5; Synonyms=SMRT-tau;
CC         IsoId=Q9Y618-5; Sequence=VSP_036595, VSP_003413;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. High levels of expression are
CC       detected in lung, spleen and brain.
CC   -!- INDUCTION: Regulated during cell cycle progression.
CC   -!- DOMAIN: The N-terminal region contains repression functions that
CC       are divided into three independent repression domains (RD1, RD2
CC       and RD3). The C-terminal region contains the nuclear receptor-
CC       interacting domains that are divided in two separate interaction
CC       domains (ID1 and ID2).
CC   -!- DOMAIN: The two interaction domains (ID) contain a conserved
CC       sequence referred to as the CORNR box. This motif is required and
CC       sufficient to permit binding to unligated TR and RARS. Sequences
CC       flanking the CORNR box determine nuclear hormone receptor
CC       specificity.
CC   -!- SIMILARITY: Belongs to the N-CoR nuclear receptor corepressors
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB91452.1; Type=Erroneous translation; Note=Wrong choice of CDS.; Evidence={ECO:0000305};
CC       Sequence=AAC50236.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC       Sequence=AAD20946.1; Type=Frameshift; Positions=787, 794; Evidence={ECO:0000305};
CC       Sequence=BAD92326.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; S83390; AAB50847.1; -; mRNA.
DR   EMBL; AF113003; AAD20946.1; ALT_FRAME; mRNA.
DR   EMBL; AF125672; AAD22973.1; -; mRNA.
DR   EMBL; AY965853; AAX77219.1; -; mRNA.
DR   EMBL; AC069261; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC073916; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AB209089; BAD92326.1; ALT_INIT; mRNA.
DR   EMBL; U80750; AAB91446.1; -; mRNA.
DR   EMBL; U80761; AAB91452.1; ALT_SEQ; mRNA.
DR   EMBL; U37146; AAC50236.1; ALT_SEQ; mRNA.
DR   PIR; S60255; S60255.
DR   RefSeq; NP_001070729.2; NM_001077261.3.
DR   RefSeq; NP_001193583.1; NM_001206654.1.
DR   RefSeq; NP_006303.4; NM_006312.5.
DR   UniGene; Hs.137510; -.
DR   PDB; 1KKQ; X-ray; 3.00 A; E/F/G/H=2347-2365.
DR   PDB; 1R2B; X-ray; 2.20 A; C/D=1422-1438.
DR   PDB; 1XC5; NMR; -; A=412-480.
DR   PDB; 2GPV; X-ray; 2.85 A; G/H/I=2346-2367.
DR   PDB; 2L5G; NMR; -; B=167-207.
DR   PDB; 2LTP; NMR; -; A=615-685.
DR   PDB; 2ODD; NMR; -; B=1109-1121.
DR   PDB; 2RT5; NMR; -; B=2518-2525.
DR   PDB; 3R29; X-ray; 2.90 A; C/D=2346-2361.
DR   PDB; 3R2A; X-ray; 3.00 A; E/F=2346-2361.
DR   PDB; 4A69; X-ray; 2.06 A; C/D=389-480.
DR   PDB; 4OAR; X-ray; 2.41 A; B=2346-2362.
DR   PDBsum; 1KKQ; -.
DR   PDBsum; 1R2B; -.
DR   PDBsum; 1XC5; -.
DR   PDBsum; 2GPV; -.
DR   PDBsum; 2L5G; -.
DR   PDBsum; 2LTP; -.
DR   PDBsum; 2ODD; -.
DR   PDBsum; 2RT5; -.
DR   PDBsum; 3R29; -.
DR   PDBsum; 3R2A; -.
DR   PDBsum; 4A69; -.
DR   PDBsum; 4OAR; -.
DR   ProteinModelPortal; Q9Y618; -.
DR   SMR; Q9Y618; -.
DR   BioGrid; 114974; 118.
DR   DIP; DIP-951N; -.
DR   IntAct; Q9Y618; 39.
DR   MINT; MINT-129997; -.
DR   STRING; 9606.ENSP00000384018; -.
DR   BindingDB; Q9Y618; -.
DR   ChEMBL; CHEMBL2111363; -.
DR   iPTMnet; Q9Y618; -.
DR   PhosphoSitePlus; Q9Y618; -.
DR   BioMuta; NCOR2; -.
DR   DMDM; 226713806; -.
DR   EPD; Q9Y618; -.
DR   PaxDb; Q9Y618; -.
DR   PeptideAtlas; Q9Y618; -.
DR   PRIDE; Q9Y618; -.
DR   Ensembl; ENST00000356219; ENSP00000348551; ENSG00000196498.
DR   GeneID; 9612; -.
DR   KEGG; hsa:9612; -.
DR   UCSC; uc058uwu.1; human. [Q9Y618-1]
DR   CTD; 9612; -.
DR   DisGeNET; 9612; -.
DR   GeneCards; NCOR2; -.
DR   H-InvDB; HIX0026341; -.
DR   HGNC; HGNC:7673; NCOR2.
DR   HPA; HPA001928; -.
DR   MIM; 600848; gene.
DR   neXtProt; NX_Q9Y618; -.
DR   PharmGKB; PA31478; -.
DR   eggNOG; KOG1878; Eukaryota.
DR   eggNOG; ENOG410YDXP; LUCA.
DR   HOVERGEN; HBG052587; -.
DR   InParanoid; Q9Y618; -.
DR   KO; K06065; -.
DR   PhylomeDB; Q9Y618; -.
DR   Reactome; R-HSA-2122947; NOTCH1 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity.
DR   Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants.
DR   Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants.
DR   Reactome; R-HSA-3214815; HDACs deacetylate histones.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-400206; Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha).
DR   SignaLink; Q9Y618; -.
DR   SIGNOR; Q9Y618; -.
DR   ChiTaRS; NCOR2; human.
DR   EvolutionaryTrace; Q9Y618; -.
DR   GeneWiki; Nuclear_receptor_co-repressor_2; -.
DR   GenomeRNAi; 9612; -.
DR   PRO; PR:Q9Y618; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000196498; -.
DR   CleanEx; HS_NCOR2; -.
DR   ExpressionAtlas; Q9Y618; baseline and differential.
DR   Genevisible; Q9Y618; HS.
DR   GO; GO:0000118; C:histone deacetylase complex; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0016604; C:nuclear body; IDA:MGI.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0017053; C:transcriptional repressor complex; IDA:BHF-UCL.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:UniProtKB.
DR   GO; GO:0016922; F:ligand-dependent nuclear receptor binding; IBA:GO_Central.
DR   GO; GO:0005112; F:Notch binding; IPI:UniProtKB.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0003714; F:transcription corepressor activity; IDA:BHF-UCL.
DR   GO; GO:0008134; F:transcription factor binding; IBA:GO_Central.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:1903799; P:negative regulation of production of miRNAs involved in gene silencing by miRNA; IMP:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:MGI.
DR   GO; GO:0072365; P:regulation of cellular ketone metabolic process by negative regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   InterPro; IPR009057; Homeobox-like.
DR   InterPro; IPR031557; N-CoR_GPS2_interact.
DR   InterPro; IPR001005; SANT/Myb.
DR   InterPro; IPR017884; SANT_dom.
DR   Pfam; PF15784; GPS2_interact; 1.
DR   Pfam; PF00249; Myb_DNA-binding; 1.
DR   SMART; SM00717; SANT; 2.
DR   SUPFAM; SSF46689; SSF46689; 2.
DR   PROSITE; PS51293; SANT; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Coiled coil;
KW   Complete proteome; DNA-binding; Methylation; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation.
FT   CHAIN         1   2525       Nuclear receptor corepressor 2.
FT                                /FTId=PRO_0000055622.
FT   DOMAIN      427    478       SANT 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00624}.
FT   DOMAIN      610    661       SANT 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00624}.
FT   REGION      254    312       Interaction with SIN3A/B. {ECO:0000250}.
FT   REGION     2139   2142       Required for interaction with RARA in the
FT                                absence of its ligand.
FT   COILED      174    215       {ECO:0000255}.
FT   COILED      522    561       {ECO:0000255}.
FT   MOTIF      2147   2151       CORNR box of ID1.
FT   MOTIF      2350   2354       CORNR box of ID2.
FT   COMPBIAS    494    510       Poly-Gln.
FT   COMPBIAS    682    685       Poly-Lys.
FT   COMPBIAS    778    820       Pro-rich.
FT   COMPBIAS    995   1003       Poly-Pro.
FT   COMPBIAS   1392   1397       Poly-Pro.
FT   COMPBIAS   1850   1854       Poly-Gly.
FT   COMPBIAS   2487   2490       Poly-Pro.
FT   MOD_RES      18     18       Asymmetric dimethylarginine.
FT                                {ECO:0000250|UniProtKB:Q9WU42}.
FT   MOD_RES      54     54       Phosphoserine.
FT                                {ECO:0000244|PubMed:18220336,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      67     67       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     149    149       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     152    152       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     156    156       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     215    215       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     493    493       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     553    553       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     554    554       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES     750    750       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     753    753       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     878    878       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     939    939       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     946    946       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     956    956       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     959    959       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1181   1181       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1218   1218       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1248   1248       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1259   1259       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1331   1331       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1391   1391       Phosphothreonine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1487   1487       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1547   1547       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1603   1603       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9WU42}.
FT   MOD_RES    1627   1627       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1661   1661       Asymmetric dimethylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES    1783   1783       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1786   1786       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1872   1872       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES    1970   1970       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    2016   2016       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    2037   2037       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    2057   2057       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES    2065   2065       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    2068   2068       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES    2069   2069       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES    2071   2071       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9WU42}.
FT   MOD_RES    2073   2073       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    2088   2088       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2214   2214       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES    2234   2234       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2269   2269       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2424   2424       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ       1   1710       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:8813722}.
FT                                /FTId=VSP_003412.
FT   VAR_SEQ     724    740       Missing (in isoform 4 and isoform 5).
FT                                {ECO:0000303|PubMed:10097068,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_036595.
FT   VAR_SEQ    1034   1041       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:10077563}.
FT                                /FTId=VSP_036596.
FT   VAR_SEQ    2361   2406       Missing (in isoform 2 and isoform 5).
FT                                {ECO:0000303|PubMed:8813722,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_003413.
FT   VARIANT     781    781       G -> E (in dbSNP:rs7978237).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_060073.
FT   VARIANT    1707   1707       A -> T (in dbSNP:rs2229840).
FT                                {ECO:0000269|PubMed:10077563,
FT                                ECO:0000269|PubMed:10097068,
FT                                ECO:0000269|PubMed:7566127,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_054751.
FT   VARIANT    2012   2012       P -> S (in dbSNP:rs2230944).
FT                                /FTId=VAR_060074.
FT   MUTAGEN    2139   2139       R->A: Abolishes interaction with the apo
FT                                LBD of RARA. Restores some interaction on
FT                                the addition of inverse agonist BMS493.
FT                                {ECO:0000269|PubMed:20543827}.
FT   MUTAGEN    2141   2141       V->P: Abolishes interaction with the apo
FT                                LBD of RARA. No change on interaction on
FT                                the addition of inverse agonist BMS493.
FT                                {ECO:0000269|PubMed:20543827}.
FT   MUTAGEN    2142   2142       T->G: Abolishes interaction with the apo
FT                                LBD of RARA. Restores some interaction on
FT                                the addition of inverse agonist BMS493.
FT                                {ECO:0000269|PubMed:20543827}.
FT   CONFLICT      7      7       P -> L (in Ref. 2; AAD20946).
FT                                {ECO:0000305}.
FT   CONFLICT    295    295       E -> K (in Ref. 2; AAD20946).
FT                                {ECO:0000305}.
FT   CONFLICT    309    309       W -> L (in Ref. 2; AAD20946).
FT                                {ECO:0000305}.
FT   CONFLICT    352    352       Missing (in Ref. 3; AAD22973 and 4;
FT                                AAX77219). {ECO:0000305}.
FT   CONFLICT    365    365       A -> P (in Ref. 3; AAD22973 and 4;
FT                                AAX77219). {ECO:0000305}.
FT   CONFLICT    612    613       SS -> EF (in Ref. 7; AAB91446).
FT                                {ECO:0000305}.
FT   CONFLICT    711    711       S -> T (in Ref. 3; AAD22973 and 4;
FT                                AAX77219). {ECO:0000305}.
FT   CONFLICT    796    796       P -> S (in Ref. 3; AAD22973 and 4;
FT                                AAX77219). {ECO:0000305}.
FT   CONFLICT    804    804       G -> L (in Ref. 3; AAD22973 and 4;
FT                                AAX77219). {ECO:0000305}.
FT   CONFLICT    814    814       S -> F (in Ref. 3; AAD22973 and 4;
FT                                AAX77219). {ECO:0000305}.
FT   CONFLICT    817    817       A -> S (in Ref. 3; AAD22973 and 4;
FT                                AAX77219). {ECO:0000305}.
FT   CONFLICT    889    889       G -> R (in Ref. 3; AAD22973 and 4;
FT                                AAX77219). {ECO:0000305}.
FT   CONFLICT   1570   1570       T -> M (in Ref. 2; AAD20946, 3; AAD22973,
FT                                4; AAX77219 and 8; AAC50236).
FT                                {ECO:0000305}.
FT   CONFLICT   1902   1902       T -> K (in Ref. 2; AAD20946, 3; AAD22973,
FT                                4; AAX77219 and 8; AAC50236).
FT                                {ECO:0000305}.
FT   CONFLICT   2502   2502       P -> A (in Ref. 1; AAB50847).
FT                                {ECO:0000305}.
FT   STRAND      168    170       {ECO:0000244|PDB:2L5G}.
FT   HELIX       171    205       {ECO:0000244|PDB:2L5G}.
FT   STRAND      414    417       {ECO:0000244|PDB:4A69}.
FT   HELIX       419    428       {ECO:0000244|PDB:4A69}.
FT   HELIX       434    446       {ECO:0000244|PDB:4A69}.
FT   HELIX       451    456       {ECO:0000244|PDB:4A69}.
FT   TURN        458    460       {ECO:0000244|PDB:1XC5}.
FT   HELIX       463    473       {ECO:0000244|PDB:4A69}.
FT   TURN        474    476       {ECO:0000244|PDB:1XC5}.
FT   HELIX       617    629       {ECO:0000244|PDB:2LTP}.
FT   TURN        630    632       {ECO:0000244|PDB:2LTP}.
FT   HELIX       634    640       {ECO:0000244|PDB:2LTP}.
FT   STRAND      642    644       {ECO:0000244|PDB:2LTP}.
FT   HELIX       646    655       {ECO:0000244|PDB:2LTP}.
FT   HELIX       661    679       {ECO:0000244|PDB:2LTP}.
FT   STRAND     1116   1118       {ECO:0000244|PDB:2ODD}.
FT   STRAND     1424   1428       {ECO:0000244|PDB:1R2B}.
FT   HELIX      2350   2358       {ECO:0000244|PDB:4OAR}.
SQ   SEQUENCE   2525 AA;  274804 MW;  9B8689CA013C4513 CRC64;
     MSGSTQPVAQ TWRATEPRYP PHSLSYPVQI ARTHTDVGLL EYQHHSRDYA SHLSPGSIIQ
     PQRRRPSLLS EFQPGNERSQ ELHLRPESHS YLPELGKSEM EFIESKRPRL ELLPDPLLRP
     SPLLATGQPA GSEDLTKDRS LTGKLEPVSP PSPPHTDPEL ELVPPRLSKE ELIQNMDRVD
     REITMVEQQI SKLKKKQQQL EEEAAKPPEP EKPVSPPPIE SKHRSLVQII YDENRKKAEA
     AHRILEGLGP QVELPLYNQP SDTRQYHENI KINQAMRKKL ILYFKRRNHA RKQWEQKFCQ
     RYDQLMEAWE KKVERIENNP RRRAKESKVR EYYEKQFPEI RKQRELQERM QSRVGQRGSG
     LSMSAARSEH EVSEIIDGLS EQENLEKQMR QLAVIPPMLY DADQQRIKFI NMNGLMADPM
     KVYKDRQVMN MWSEQEKETF REKFMQHPKN FGLIASFLER KTVAECVLYY YLTKKNENYK
     SLVRRSYRRR GKSQQQQQQQ QQQQQQQQQQ PMPRSSQEEK DEKEKEKEAE KEEEKPEVEN
     DKEDLLKEKT DDTSGEDNDE KEAVASKGRK TANSQGRRKG RITRSMANEA NSEEAITPQQ
     SAELASMELN ESSRWTEEEM ETAKKGLLEH GRNWSAIARM VGSKTVSQCK NFYFNYKKRQ
     NLDEILQQHK LKMEKERNAR RKKKKAPAAA SEEAAFPPVV EDEEMEASGV SGNEEEMVEE
     AEALHASGNE VPRGECSGPA TVNNSSDTES IPSPHTEAAK DTGQNGPKPP ATLGADGPPP
     GPPTPPPEDI PAPTEPTPAS EATGAPTPPP APPSPSAPPP VVPKEEKEEE TAAAPPVEEG
     EEQKPPAAEE LAVDTGKAEE PVKSECTEEA EEGPAKGKDA EAAEATAEGA LKAEKKEGGS
     GRATTAKSSG APQDSDSSAT CSADEVDEAE GGDKNRLLSP RPSLLTPTGD PRANASPQKP
     LDLKQLKQRA AAIPPIQVTK VHEPPREDAA PTKPAPPAPP PPQNLQPESD APQQPGSSPR
     GKSRSPAPPA DKEAEKPVFF PAFAAEAQKL PGDPPCWTSG LPFPVPPREV IKASPHAPDP
     SAFSYAPPGH PLPLGLHDTA RPVLPRPPTI SNPPPLISSA KHPSVLERQI GAISQGMSVQ
     LHVPYSEHAK APVGPVTMGL PLPMDPKKLA PFSGVKQEQL SPRGQAGPPE SLGVPTAQEA
     SVLRGTALGS VPGGSITKGI PSTRVPSDSA ITYRGSITHG TPADVLYKGT ITRIIGEDSP
     SRLDRGREDS LPKGHVIYEG KKGHVLSYEG GMSVTQCSKE DGRSSSGPPH ETAAPKRTYD
     MMEGRVGRAI SSASIEGLMG RAIPPERHSP HHLKEQHHIR GSITQGIPRS YVEAQEDYLR
     REAKLLKREG TPPPPPPSRD LTEAYKTQAL GPLKLKPAHE GLVATVKEAG RSIHEIPREE
     LRHTPELPLA PRPLKEGSIT QGTPLKYDTG ASTTGSKKHD VRSLIGSPGR TFPPVHPLDV
     MADARALERA CYEESLKSRP GTASSSGGSI ARGAPVIVPE LGKPRQSPLT YEDHGAPFAG
     HLPRGSPVTT REPTPRLQEG SLSSSKASQD RKLTSTPREI AKSPHSTVPE HHPHPISPYE
     HLLRGVSGVD LYRSHIPLAF DPTSIPRGIP LDAAAAYYLP RHLAPNPTYP HLYPPYLIRG
     YPDTAALENR QTIINDYITS QQMHHNAATA MAQRADMLRG LSPRESSLAL NYAAGPRGII
     DLSQVPHLPV LVPPTPGTPA TAMDRLAYLP TAPQPFSSRH SSSPLSPGGP THLTKPTTTS
     SSERERDRDR ERDRDREREK SILTSTTTVE HAPIWRPGTE QSSGSSGSSG GGGGSSSRPA
     SHSHAHQHSP ISPRTQDALQ QRPSVLHNTG MKGIITAVEP STPTVLRSTS TSSPVRPAAT
     FPPATHCPLG GTLDGVYPTL MEPVLLPKEA PRVARPERPR ADTGHAFLAK PPARSGLEPA
     SSPSKGSEPR PLVPPVSGHA TIARTPAKNL APHHASPDPP APPASASDPH REKTQSKPFS
     IQELELRSLG YHGSSYSPEG VEPVSPVSSP SLTHDKGLPK HLEELDKSHL EGELRPKQPG
     PVKLGGEAAH LPHLRPLPES QPSSSPLLQT APGVKGHQRV VTLAQHISEV ITQDYTRHHP
     QQLSAPLPAP LYSFPGASCP VLDLRRPPSD LYLPPPDHGA PARGSPHSEG GKRSPEPNKT
     SVLGGGEDGI EPVSPPEGMT EPGHSRSAVY PLLYRDGEQT EPSRMGSKSP GNTSQPPAFF
     SKLTESNSAM VKSKKQEINK KLNTHNRNEP EYNISQPGTE IFNMPAITGT GLMTYRSQAV
     QEHASTNMGL EAIIRKALMG KYDQWEESPP LSANAFNPLN ASASLPAAMP ITAADGRSDH
     TLTSPGGGGK AKVSGRPSSR KAKSPAPGLA SGDRPPSVSS VHSEGDCNRR TPLTNRVWED
     RPSSAGSTPF PYNPLIMRLQ AGVMASPPPP GLPAGSGPLA GPHHAWDEEP KPLLCSQYET
     LSDSE
//
